Literature DB >> 1781415

Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.

P Rubin1, L Dubé, R Braeckman, L Swanson, R Hansen, D Albert, G Carter.   

Abstract

Zileuton is a potent and specific inhibitor of 5-lipoxygenase, the first dedicated enzyme in the metabolism of arachidonic acid to the leukotrienes. The leukotrienes have been implicated in numerous pathological conditions. Zileuton was given to normal human volunteers in single doses of 200 mg to 800 mg. Results of these studies indicated that zileuton was well absorbed orally with an elimination half-life of approximately 2.5 hours. Leukotriene B4 production by ex vivo calcium ionophone stimulated whole blood was inhibited by up to 80% of baseline and correlated with plasma concentrations. Zileuton did not significantly inhibit cyclooxygenase as demonstrated by thromboxane B2 levels. There were no safety concerns that would preclude development.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1781415

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  10 in total

1.  The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.

Authors:  W M Awni; J H Cavanaugh; R A Braeckman; S Y Chu; K J Patterson; J M Machinist; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.

Authors:  W M Awni; R A Braeckman; G R Granneman; G Witt; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

3.  Effect of zileuton on theophylline pharmacokinetics.

Authors:  G R Granneman; R A Braeckman; C S Locke; J H Cavanaugh; L M Dubé; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

4.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.

Authors:  E Samara; J H Cavanaugh; D Mukherjee; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.

Authors:  S L Wong; W M Awni; J H Cavanaugh; T el-Shourbagy; C S Locke; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

7.  Phenotyping drug polypharmacology via eicosanoid profiling of blood.

Authors:  Jiao Song; Xuejun Liu; Tadimeti S Rao; Leon Chang; Michael J Meehan; Jonathan M Blevitt; Jiejun Wu; Pieter C Dorrestein; Marcos E Milla
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

8.  In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.

Authors:  J M Machinist; M J Kukulka; B A Bopp
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.

Authors:  W M Awni; G R Granneman; C S Locke; S R Brandwein; L M Dube
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Let-7 microRNA-dependent control of leukotriene signaling regulates the transition of hematopoietic niche in mice.

Authors:  Xuan Jiang; John S Hawkins; Jerry Lee; Carlos O Lizama; Frank L Bos; Joan P Zape; Prajakta Ghatpande; Yongbo Peng; Justin Louie; Giorgio Lagna; Ann C Zovein; Akiko Hata
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.